SPRC
SciSparc·NASDAQ
--
--(--)
--
--(--)
0.87 / 10
Underperform
NeuroThera Labs, operating under SciSparc, holds a newly granted U.S. patent for cannabinoid technology targeting antibiotic resistance, a positive fundamental driver. However, core financial metrics remain weak: days sales outstanding are high at 287.77, and year-over-year revenue growth is sharply negative at -45.12%, indicating ongoing operational challenges that outweigh the patent's near-term benefit.
Analysis Checks(1/4)
Total operating revenue (YoY growth rate %)
Value-45.12
Score0/3
Weight42.13%
1M Return-6.11%
Value-45.12
Score0/3
Weight42.13%
1M Return-6.11%
Interest coverage ratio (EBIT / Interest expense) (%)
Value27.58
Score2/3
Weight9.09%
1M Return-1.11%
Value27.58
Score2/3
Weight9.09%
1M Return-1.11%
Days sales outstanding
Value287.77
Score1/3
Weight12.52%
1M Return-1.57%
Value287.77
Score1/3
Weight12.52%
1M Return-1.57%
Operating revenue (YoY growth rate %)
Value-45.12
Score0/3
Weight36.26%
1M Return-5.06%
Value-45.12
Score0/3
Weight36.26%
1M Return-5.06%
Total operating revenue (YoY growth rate %)
Value-45.12
Score0/3
Weight42.13%
1M Return-6.11%
Value-45.12
Score0/3
Weight42.13%
1M Return-6.11%
Days sales outstanding
Value287.77
Score1/3
Weight12.52%
1M Return-1.57%
Value287.77
Score1/3
Weight12.52%
1M Return-1.57%
Interest coverage ratio (EBIT / Interest expense) (%)
Value27.58
Score2/3
Weight9.09%
1M Return-1.11%
Value27.58
Score2/3
Weight9.09%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value-45.12
Score0/3
Weight36.26%
1M Return-5.06%
Value-45.12
Score0/3
Weight36.26%
1M Return-5.06%
Is SPRC undervalued or overvalued?
- SPRC scores 0.87/10 on fundamentals and holds a Premium valuation at present. Backed by its -210.61% ROE, -1424.49% net margin, -0.55 P/E ratio, -42.98 P/B ratio, and -13.27% earnings growth, these metrics solidify its Underperform investment rating.
